Stockreport

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress [Yahoo! Finance]

Jasper Therapeutics, Inc. - Class A  (JSPR) 
PDF focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), [Read more]